Mr. Dennis is the President of his own consulting company, Rocky Mountain Med Tech, and has over 30 years of experience in the medical device industry. In addition to Velomedix he serves on the Boards of MVG Development, where he is Executive Chairman, Reglera Inc, and Mederi Therapeutics. Prior to starting his own consulting business, Mr. Dennis served as World Wide President for Johnson & Johnson’s Biosense Webster division. Earlier in his career, he served as President of the Cardiac Rhythm Management Division for St. Jude Medical, President and CEO of Telectronics Pacing Systems, and Vice President of Operations for Nellcor, Inc. His medical device career began with IVAC Corporation, a pioneer in the development of IV instrumentation and electronic temperature devices. Mr. Dennis received a BA in Business Administration and an MBA from National University in San Diego, CA.
Mr. Galletti is a founder and Managing Director of Longitude Capital. He focuses on investments in medical devices and specialty pharmaceuticals, including drug-device combinations. From 2003 to 2006, Mr. Galletti was a Senior Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, Mr. Galletti worked at Amerindo Investment Advisors and Vector Fund Management focusing on healthcare. Mr. Galletti has also worked in the Global Healthcare Investment Banking Group at J.P. Morgan & Co. Mr. Galletti began his life sciences industry career at APM, a management consultancy dedicated to improving operations performance within large acute-care hospitals. Mr. Galletti currently serves on the Boards of Aptus Endosystems and Velomedix. Mr. Galletti also sits or has sat on advisory boards for the Innovation and New Ventures Office at Northwestern University, the Program for Biomedical Engineering at Brown University, and AdvaMed. Mr. Galletti holds an MBA from the Kellogg School of Management at Northwestern University and an AB from Princeton University.
Mr. Ludlum is Chief Financial Officer of EndoGastric Solutions, Inc. where he has served since April 2011. Mr. Ludlum served as Senior Vice President and Chief Financial Officer of Paracor Medical from 2008 to 2009. From 2005 through 2007 Mr. Ludlum was an investor, advisor, and board member for several medical technology companies. He was President, Chief Executive Officer, and Chairman of the Board of Directors of Revivant Corporation from 2003 until its sale to Zoll Medical Corporation in late 2004. Prior to that, he was Chief Financial Officer of Perclose, Inc. for five years. Mr. Ludlum currently serves on the Board of Directors of several private medical technology companies and is on the Board of Directors of NATUS Medical (NASDAQ:BABY) and was a director of SOLTA Medical (previously Thermage, Inc. Nasdaq: THRM) from 2004 to 2007. He holds a BS in Business from Lehigh University and an MBA from Columbia University Graduate School of Business.
Mr. Cleeland is an executive with 24 years in the medical device industry. Andrew has recently joined Twelve as its President and CEO. Andrew was the president and CEO of Ardian, Inc. prior to its recent acquisition by Medtronic. Andrew’s experience includes both private and public sector roles. Andrew started with the Australian Government’s Therapeutic Goods Administration, progressed to two large medtech companies, Telectronics Pacing Systems and Baxter Healthcare, and then to three Bay Area start-ups, Radiant Medical, Ardian, Inc. (including a brief stint at Medtronic following its acquisition of Ardian) and Foundry NewCo XII. He holds a Bachelor of Applied Science (Biophysics) from the Swinburne Institute of Technology.
Prior to Velomedix, Mr. Gold was a Venture Partner for Longitude Capital where he focused on investments in medical devices. From 2001-2005 he was Chief Executive Officer of CryoVascular Systems, a medical device company developing treatments for peripheral vascular disease. CryoVascular was acquired by Boston Scientific Corporation in 2005. From 1997 to 2000, Mr. Gold was COO and Executive Vice President of CardioThoracic Systems (NASDAQ: CTSI), a medical device company focused on developing products to enable off-pump open-heart surgery. CTSI was acquired by Guidant Corporation. Prior to CTSI, Mr. Gold spent 18 years with Cordis Corporation, now the primary cardiovascular device subsidiary of Johnson & Johnson, in a series of roles of increasing responsibility and scope. He was co-founder and President of Cordis Endovascular Systems, the subsidiary company that initially focused on the interventional neuroradiology and peripheral markets. Mr. Gold holds an MBA from the University of Florida and a BS in Engineering from Northeastern University and is a graduate of GE’s Manufacturing Management Program.